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Simple Summary: Colorectal cancer (CRC) is amongst the deadliest cancers. Surgical excision of the
primary tumor is the curative intent treatment; however, recurrence occurs in approximately 20% of
patients. Therefore, novel staging protocols are crucial to inform clinicians which patients will recur.
In this study, we explored the prognostic potential of tumor-infiltrating lymphocytes. Our data did
not reveal any association between intratumor lymphocyte infiltrations with clinical or pathological
data. On the other hand, the presence of CD3+, CD8+, or FoxP3+ lymphocyte infiltration in the
tumor invasive margins were associated with markers of good prognosis. Despite this, we were not
able to find any statistically significant alterations in the overall survival of patients, even though
high infiltrations of FoxP3+ T lymphocytes in the tumor margin resulted in an increased overall
survival of 14 months. Taken together, our data show that the location and type of tumor-infiltrating
lymphocytes are associated with the pathogenesis of CRC; however, only high FoxP3+ T lymphocyte
infiltrations are inclined to indicate favorable prognosis.
Abstract: Tumor-infiltrating lymphocytes include heterogeneous populations of T lymphocytes
that play crucial roles in the tumor immune response; importantly, their presence in the tumor
tissue may predict clinical outcomes. Therefore, we herein studied the prognostic significance of the
presence and location of CD3+, CD8+, and FoxP3+ T lymphocytes in colorectal cancer samples. In
the intratumor analysis, our data did not reveal any association between lymphocyte infiltrations
with clinical or pathological data. However, in the tumor margins, we found that the presence of
high infiltrations of CD3+, CD8+, or FoxP3+ T lymphocytes were associated with TNM stages I-II
(p = 0.021, p = 0.022, and p = 0.012, respectively) and absence of lymph node metastases (p = 0.010,
p = 0.003, and p = 0.004, respectively). Despite these associations with good prognostic indicators, we
were not able to find any statistically significant alterations in the overall survival of the patients,
even though high infiltrations of FoxP3+ T lymphocytes in the tumor margins resulted in an increased
overall survival of 14 months. Taken together, these data show that the presence of CD3+, CD8+,
or FoxP3+T lymphocyte infiltrates in the tumor margins are associated with the pathogenesis of
CRC, but only high Foxp3+ T lymphocyte infiltrations in the tumor invasive margins are inclined to
indicate favorable prognosis.
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1. Introduction
Colorectal cancer (CRC) is the third most common type of cancer worldwide, and
its occurrence is responsible for nearly 10% of all deaths related to malignancies [1]. His-
torically, the incidence of CRC has been low at ages younger than 50 years; however, in
recent years, there has been a rising incidence of CRC at these ages [2]. This emerging
trend is prompting a rapid increase in the number of CRC cases in previously low-risk
countries, a phenomenon ascribed to changes in dietary patterns and risk factors towards a
more western lifestyle [3]. The cornerstone of curative intent treatment for CRC remains
surgical excision of the primary tumor [4]. While this approach is curative for most patients,
recurrence of CRC disease occurs in approximately 20% of patients [5]. Therefore, after
tumor resection, clinicians often have follow-up appointments with patients to detect any
recurrence at an early and treatable stage. These follow-ups have unraveled the need for
novel predictive prognosis biomarkers and well-established staging protocols to inform
clinicians which patients will recur.
The American Joint Committee on Cancer first defined the Tumor Node Metastasis
(TNM) staging system to inform on patients’ prognosis [6]. Currently, TNM is the most
widely used staging system for CRC, and its application in the clinic has been crucial to
inform patients’ prognosis, also having a considerable and direct impact on the treatment
that patients receive [6]. However, clinical evidence suggests that the outcome of the
disease varies significantly among patients within the same TNM stage [7–9]. This is
particularly noticeable at TNM stage II, wherein one-third of all patients may still die
of recurrent disease [10,11]. Contrarily, patients at TNM stage III may be cured of the
disease by surgery alone [12]. As such, under or overtreatment may occur between stages
determined by the TNM system, as previously demonstrated [13,14]. Additionally, the
lack of consensus on the application of TNM staging and the constant update of revised
versions are significant hurdles in comparing different cohorts [9,15,16]. Therefore, clinical
practice may benefit from the inclusion of other staging methodologies to discriminate
patients who may benefit from additional therapies, such as adjuvant chemotherapies.
Over the last decade, there has been a progressive increase in our understanding of
the tumor microenvironment, which prompted the identification of key players of the
immune response to tumors. Particularly important and with prognostic potential in
CRC are tumor-infiltrating lymphocytes (TIL), which are heterogeneous populations of T
lymphocytes present in the tumor microenvironment [17–21]. In this regard, the presence
of CD8+ T lymphocytes has been associated with good prognosis in different types of
solid tumors [22,23]. This T lymphocyte population mediates anti-tumor activity through
antigen-specific cytotoxicity and by producing anti-tumor cytokines, namely IFN-γ and
TNF-α [24,25]. On the other hand, increased tumor infiltration by FoxP3-expressing T
lymphocytes has been associated with reduced overall survival of patients with different
types of cancer, including breast [26], lung [27], and cervical cancers [28]. However, this
association is not seen in all cancer types, as FoxP3+ T lymphocyte infiltrates have been
associated with good prognosis in other cancers, such as head and neck cancers [29]. In
colorectal cancer, FoxP3+ T lymphocyte infiltrates have been associated with good and
bad prognosis by different studies [30–33]. Taken together, these data warrant further
investigation on the prognostic potential of FoxP3+ T lymphocytes in colorectal cancer.
The analysis of immune infiltrates and their correlation with patients’ pathological
records originated the development of staging methods based on the intratumor and
invasive margin infiltration of CD3+ and CD8+ T lymphocytes [34]. While the predictive
capacity of TNM staging is more reliable than alternative methods, such as DNA content
or genetic features, the analysis of tumor immune infiltrate has been suggested to surpass
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the TNM classification in multivariate analyses [35]. Indeed, after adjusting for TNM stage,
recent data suggest that the density of CD3+ T lymphocytes remained as an independent
prognostic factor [36]. Furthermore, patients with low numbers of tumor-infiltrating CD8+
T lymphocytes relapsed more independently of the T stage of the tumor [19]. These data
demonstrate the high prognostic utility of TILs in staging CRC patients. However, as
discussed above, the interaction between different populations of TILs in the tumor or
invasive margin may influence tumor progression or control. As such, it is crucial to define
the prognostic utility of the different populations of T lymphocytes.
In this work, we analyzed the presence of lymphocyte infiltrates, specifically CD3+,
CD8+, and FoxP3+ T lymphocytes, in CRC tumors including their invasive margins to
evaluate their association with clinicopathological information and overall survival of
patients. We did not find any associations between the presence and extent of intratumor
T lymphocyte infiltrations with the clinical or pathological data of the patients. On the
other hand, the infiltration of CD3+, CD8+, or FoxP3+ lymphocytes in the tumor invasive
margins were associated with the pathogenesis of CRC, but only FoxP3+ T lymphocyte
infiltrations were inclined to indicate favorable prognosis.
2. Materials and Methods
2.1. Patients Specimens
A total of 194 samples of colorectal cancer (CRC) at stage I to IV were used in this
retrospective study. These samples were collected from patients diagnosed with CRC
that underwent surgical excision of the primary tumor at the Hospital of Braga, Portugal,
between January 2005 and January 2010. The CRC tissue extracted during the surgery was
formalin-fixed and embedded in paraffin. Clinical and pathological data was available for
184 cases and was obtained through medical charts and pathology reports (Table 1).
Table 1. Demographic and baseline characteristics of the patients.
Parameter N Parameter N Parameter N
Gender Time toDiagnosis TNM
Male 120 <6 months 126 I-II 50
Female 64 >6 months 24 III-IV 134
Age (years) Localization Histological Type
≤45 5 Colon 129 Adenocarcinoma 170
>45 179 Rectum 55 Mucinous 12
Previous tumors CEA (ng/mL) Signet ring andmucinous 2
Without 150 ≤10 132 Differentiation
With 34 >10 22
Well/Moderately 167
Poorly/Undifferentiated 16
Family History Metastasis Lymph node metastasis
Without 156 No 138 Without 106
With 15 Yes 46 With 77
Presentation Tumor size(cm)
Asymptomatic 34 ≤4.5 107
Symptomatic 150 >4.5 70
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2.2. Immunohistochemistry
Tumor-infiltrating lymphocytes were detected by immunohistochemistry using an-
tibodies against CD3 (MCA1477, BioRad), CD8 (ab4055, Abcam), or FoxP3 (14477782,
Invitrogen). Briefly, whole-tissue sections were deparaffinized and hydrated to prepare the
tissue for the staining. The slides from whole-tissue sections were incubated for 30 min
in citrate buffer at 96 ◦C followed by incubation in hydrogen peroxide for 10 min at room
temperature (RT). The slides were then incubated for 1 h with blocking solution (PBS
with 5% BSA and 0.05% Tween 20) before incubation with primary antibodies at 4 ◦C
for 16 h. After washing with PBS, the slides were incubated with biotinylated-secondary
antibodies for 1 h at RT. Slides were then incubated with streptavidin for 1 h followed
by an incubation with chromogen (DAB; Dako) for 10 min, and then counterstained with
hematoxylin. Amygdala sections were used as positive controls.
Immunostaining analysis was used to determine the presence of CD3, CD8, or FoxP3
infiltrates in the tumor, tumor invasive margins, and normal adjacent colon epithelium
using an Olympus BX41 microscope. Immunostaining was considered positive whenever
there was cytoplasmatic and membrane staining for CD3, membrane staining for CD8,
and nuclei staining for FoxP3. Grading of the immunostaining was performed in a blind
fashion by consensus of two experienced pathologists, without having prior knowledge
of the pathological stage or any other clinical or follow-up data for each case. Briefly, all
samples were first analyzed under the microscope at a magnification of 100× to determine
the extent of infiltration for each marker. From this analysis, the grade of CD3 and CD8
infiltration was categorized as <10%, 10–50%, or >50%, and the grade of FoxP3 infiltration
was categorized as <10%, 10–30%, or >30%, as the expression of this marker was less
extensive than of CD3 or CD8. Ten high magnification fields (×400) from each region of the
tumor were then semi-quantitatively analyzed to determine the number of lymphocytes
that stained positive for each marker.
For statistical analysis, each section was then classified as either low (<50%) or high
(>50%). Representative images (Figure 1) were obtained under brightfield microscopy
(Olympus BX61) and were recorded with a digital camera (DP70) using the Cell∧P software.
2.3. Statistical Analysis
Statistical analysis was performed using the Statistical Package for the Social program
Science (SPSS), version 24.0, SPSS Inc.®, Chicago, IL, USA.
Simple descriptive analyses were performed, determining the total number of cases
and relative frequencies for each clinical-pathological factor. To assess the existence of any
association of clinical or pathological data with immunohistochemistry results, Pearson’s
chi-square test and Fisher’s exact test (scattered data) were performed. Survival analysis
was performed using Kaplan-Meier curves and significant differences were determined by
the log-rank test. Survival was defined between the period of analysis and death from any
cause. Patients who quit the study were censored on the date of the last contact. Confidence
values (p) below 0.05 were considered statistically significant.
2.4. Ethics Statement
The study was approved by the Ethics Committee for Research in Life and Health
Sciences at University of Minho (CEICVS 004/2020) and by the Ethics Committee of
Hospital de Braga (32/2013).




Figure 1. Immunohistochemistry (IHC) of CD3, CD8, and FoxP3 T lymphocytes in CRC. Representative IHC showing low 





















































Figure 1. Immunohistochemistry (IHC) of CD3, CD8, and FoxP3 T lymphocytes in CRC. Representative IHC showing low
and high CD3+, CD8+, and FoxP3+ T lymphocytes densities. Magnification: 200×.
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3. Results
3.1. CD3+, CD8+, or FoxP3+ T Lymphocyte Infiltrations Are Higher in the Tumor Tissue Than in
the Normal Adjacent Tissue
To explore the association between tumor-infiltrating T lymphocyte populations with
CRC prognosis, we determined the infiltration of CD3+, CD8+, or FoxP3+ T lymphocytes
within the tumor, tumor margins, and in the normal adjacent tissue by immunohistochem-
istry. We began by analyzing the extension of immunostaining for the different lymphocyte
markers in the different regions of the samples (Table 2). This analysis revealed a high
intratumor infiltration of CD3+ T lymphocytes in 53% (103/194) of samples. When we
compared the proportion of infiltrating lymphocytes that were CD8+ or FoxP3+, we found a
high intratumor infiltration of CD8+ T lymphocytes in 52% (97/187) and a high intratumor
infiltration of FoxP3+ T lymphocytes in 53% (103/196) of samples (Table 2). Regarding the
infiltration of lymphocytes in the tumor margin, we also found a high infiltration of CD3+
T lymphocytes in 59% (113/192), CD8+ T lymphocytes in 58% (107/185), and FoxP3+ T
lymphocytes in 59% (114/194) of samples (Table 2). On the other hand, the extension of T
lymphocyte infiltration in the normal adjacent tissue was lower than in the tumor tissue.
Indeed, we found a high infiltration of CD3+ T lymphocytes only in 43% (61/143), CD8+
T lymphocytes in 41% (57/139), and FoxP3+ T lymphocytes in 42% (62/146) of samples
(Table 2).
Table 2. Distribution of cases according to the expression of CD3, FoxP3 and CD8 markers.
IHC Markers
CD3 FoxP3 CD8
N Low (%) High (%) N Low (%) High (%) N Low (%) High (%)
Intratumor Tissue 194 91 (47%) 103 (53%) 194 92 (47%) 102 (53%) 187 90 (48%) 97 (52%)
Tumor Margin Tissue 192 79 (41%) 113 (59%) 194 80 (41%) 114 (59%) 185 78 (42%) 107 (58%)
Normal Adjacent Tissue 143 84 (59%) 61 (43%) 146 84 (58%) 62 (42%) 139 82 (59%) 57 (41%)
We then determined the association between lymphocyte infiltration within the dif-
ferent tissues analyzed. As shown in Table 3, the high intratumor infiltration of CD3+ T
lymphocytes correlated with high infiltration of the same population in the tumor mar-
gin (p < 0.001). Similarly, the high infiltration CD3+ T lymphocytes of the tumor margin
correlated with high infiltration of the same population in the normal adjacent tissue
(p < 0.001). However, there was no correlation between the intratumor infiltrations of CD3+
T lymphocytes with the infiltration of these cells in normal adjacent tissue, indicating that
these cells were actively recruited to the tumor. The same results were obtained for CD8+
and FoxP3+ T lymphocytes (p < 0.001 for all samples).
Table 3. Correlation of marker’s expression according to the different regions analyzed.
Parameter
CD3 Intratumor CD3 Tumor Margin
N Low (%) High (%) p N Low (%) High (%) p
CD3 Tumor margin
Low (%) 78 52 (66.7) 26 (33.3) <0.001 - - - -
High (%) 112 37 (33) 75 (67) - - -
CD3 Normal adjacent
Low (%) 84 44 (52.4) 40 (47.6) 0.114 83 46 (55.4) 37 (44.6) <0.001
High (%) 59 23 (39) 36 (61) 60 13 (21.7) 47 (78.3)
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Table 3. Cont.
Parameter
FoxP3 Intratumor FoxP3 Tumor Margin
N Low (%) High (%) p N Low (%) High (%) p
FoxP3 Tumor margin
Low (%) 79 55 (69.6) 24 (30.4) <0.001 - - - -
High (%) 114 38 (33.3) 76 (63.7) - - -
FoxP3 Normal adjacent
Low (%) 84 44 (52.4) 40 (47.6) 0.175 83 47 (56.6) 36 (43.4) <0.001
High (%) 61 25 (41) 36 (59) 61 14 (23) 47 (77)
Parameter
CD8 Intratumor CD8 Tumor Margin
N Low (%) High (%) p N Low (%) High (%) p
CD8 Tumor margin
Low (%) 78 53 (28.8) 24 (31.2) <0.001 - - - -
High (%) 105 35 (33.3) 70 (66.7) - - -
CD8 Normal adjacent
Low (%) 82 43 (52.4) 39 (47.6) 0.189 81 46 (56.8) 35 (43.2) <0.001
High (%) 56 23 (41.1) 33 (58.9) 55 14 (25.5) 41 (74.5)
Taken together, these data show that a significant proportion of samples had high
T lymphocyte infiltrates and that the profile of infiltration is similar between the tumor
and the margins. Furthermore, the infiltration of lymphocytes increased from the normal
adjacent tissue to the tumor tissue.
3.2. High Intratumor Infiltration of FoxP3+ T Lymphocytes in Less Severe CRC Lesions
With the above data showing the presence of TIL in all tumor samples analyzed,
we then sought to determine whether the degree of intratumor lymphocyte infiltration
influenced CRC clinical outcome. To do this, we correlated the extension of intratumor infil-
tration of CD3+, CD8+, or FoxP3+ T lymphocytes with the clinicopathological information
of CRC patients.
Our analysis revealed no association between the clinical parameters with the ex-
tension of intratumor lymphocyte infiltration for all the immune populations analyzed
(Table 4).
Table 4. Association of intratumor infiltration of CD3+, FoxP3+, and CD8+ T lymphocytes with clinical data.
Parameter
CD3 FoxP3 CD8
N Low (%) High (%) p N Low (%) High (%) p N Low (%) High (%) p
Gender
Male 120 57 (47.5) 63 (52.5) 0.273 123 60 (48.8) 63 (51.2) 0.391 116 57 (49.1) 59 (50.9) 0.477
Female 64 25 (39.1) 39 (60.9) 64 27 (42.2) 37 (57.8) 62 27 (43.5) 35 (56.5)
Age (years)
≤45 5 3 (60) 2 (40) 0.481 5 3 (60) 2 (40) 0.540 5 3 (60) 2 (40) 0.561
>45 179 79 (44.1) 100 (55.9) 182 84 (46.2) 9 (53.8) 173 81 (46.8) 92 (53.2)
Previous
tumors
Without 150 67 (44.7) 83 (55.3) 0.954 152 71 (46.7) 81 (53.3) 0.915 147 69 (46.9) 78 (53.1) 0.883
With 34 15 (44.1) 19 (55.9) 35 16 (45.7) 19 (54.3) 31 15 (48.4) 16 (51.6)
Family
History
Without 156 73 (4.8) 83 (53.2) 0.135 159 77 (48.4) 82 (51.6) 0.106 152 74 (48.7) 78 (51.3) 0.214
With 15 4 (26.7) 11 (73.3) 15 4 (26.7) 11 (73.3) 13 4 (30.8) 9 (69.2)
Presentation
Asymptomatic 34 18 (52.9) 16 (47.1) 0.276 34 19 (55.9) 15 (44.1) 0.226 33 18 (54.5) 15 (45.5) 0.348
Symptomatic 150 64 (42.7) 86 (57.3) 153 68 (44.4) 85 (55.6) 145 66 (45.5) 79 (54.5)




N Low (%) High (%) p N Low (%) High (%) p N Low (%) High (%) p
Time to
Diagnosis
<6 months 126 57 (45.2) 69 (54.8) 0.145 129 61 (47.3) 68 (52.7) 0.101 121 59 (48.8) 62 (51.5) 0.078
>6 months 24 7 (29.2) 17 (70.8) 24 7 (29.2) 17 (70.8) 24 7 (29.2) 17 (70.8)
Localization
Colon 129 57 (44.2) 72 (55.8) 0.874 131 61 (46.6) 70 (53.4) 0.986 124 60 (48.4) 64 (51.6) 0.628
Rectum 55 25 (45.5) 30 (54.5) 56 26 (46.4) 30 (53.6) 54 24 (44.4) 30 (55.6)
We then analyzed the association between the pathological parameters with the
extension of intratumor lymphocyte infiltrations (Table 5). As for clinical parameters, our
analysis did not find any association between pathological parameters and the extension
of intratumor T lymphocyte infiltration for all the immune populations analyzed (Table 5).
Table 5. Association of intratumor infiltration of CD3+, FoxP3+, and CD8+ T lymphocytes with pathological data.
Parameter
CD3 FoxP3 CD8
N Low (%) High (%) p N Low (%) High (%) p N Low (%) High (%) p
CEA (ng/mL)
≤10 132 57 (43.2) 75 (56.8) 0.075 134 60 (44.8) 74 (55.2) 0.153 131 60 (45.8) 71 (54.2) 0.097
>10 22 14 (63.6) 8 (36.4) 23 14 (60.9) 9 (30.1) 18 12 (66.7) 6 (33.3)
Metastasis
No 138 57 (41.3) 81 (58.7) 0.123 141 61 (43.3) 80 (56.7) 0.117 135 60 (44.4) 76 (55.6) 0.193
Yes 46 25 (54.3) 21 (45.7) 46 26 (56.5) 20 (43.5) 43 24 (55.8) 19 (44.2)
Tumor Size (cm)
≤4.5 107 49 (45.8) 58 (54.2) 0.844 110 52 (47.3) 58 (52.7) 0.942 103 49 (47.6) 54 (52.4) 0.830
>4.5 70 31 (44.3) 39 (55.7) 69 33 (47.8) 36 (52.2) 67 33 (49.3) 34 (50.7)
Histological Type
Adenocarcinoma 170 75 (44.1) 95 (55.9) 0.913 172 79 (45.9) 93 (54.1) 0.751 163 76 (46.6) 87 (53.4) 0.773
Mucinous 12 6 (50) 6 (50) 12 6 (50) 6 (50) 12 6 (50) 6 (50)
Signet ring and
mucinous 2 1 (50) 1 (50) 3 2 (66.7) 1 (33.3) 3 2 (66.7) 1 (33.3)
Differentiation
Well/Moderately 167 73 (43.7) 94 (56.3) 0.473 168 77 (45.8) 91 (54.2) 0.425 169 74 (46.5) 85 (53.4) 0.458
Poorly/Undifferentiated 15 8 (53.3) 7 (46.7) 16 9 (56.3) 7 (43.8) 16 9 (56.3) 7 (43.8)
Lymph Node
Metastasis
Without 106 44 (41.5) 62 (58.5) 0.292 106 45 (42.5) 61 (57.5) 0.126 101 44 (43.6) 57 (56.4) 0.17
With 77 38 (49.4) 39 (50.6) 78 42 (53.8) 36 (46.2) 74 40 (54.1) 34 (45.9)
TNM
I-II 50 21 (42) 29 (58) 0.669 51 20 (39.2) 31 (60.8) 48 19 (39.5) 29 (60.4) 0.201
III-IV 134 61 (45.5) 73 (54.5) 135 67 (49.6) 68 (50.4) 129 65 (50.4) 64 (49.6)
Overall survival
Months ± SD 184 106.8 ±7.5 93.3 ± 7.2 0.294 187
103.4 ±
7.2 98.1 ± 7.3 0.598 178
103.3 ±
7.5 94.0 ± 7.5 0.358
These data show that the extent of intratumor T lymphocyte infiltrations does not
impact the pathogenesis of CRC.
3.3. High CD3+, CD8+, or FoxP3+ T Lymphocytes in the Tumor Margins Are Associated with
Good Prognostic Indicators
As we found high lymphocyte infiltrates in the tumor margins of a significant num-
ber of samples, we next determined if the accumulation of CD3+, CD8+ or FoxP3+ T
lymphocytes were associated with any CRC clinical or pathological parameters.
Our analysis did not uncover any association with clinical parameters (Table 6).
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Table 6. Association of tumor margin infiltration of CD3+, FoxP3+, and CD8+ T lymphocytes with clinical data.
Parameter
CD3 FoxP3 CD8
N Low (%) High (%) p N Low (%) High (%) p N Low (%) High (%) p
Gender
Male 118 48 (40.7) 70 (59.3) 0.303 122 51 (41.8) 71 (58.2) 0.296 115 49 (42.6) 66 (57.4) 0.529
Female 62 22 (35.5) 40 (64.5) 63 23 (36.5) 40 (63.5) 61 23 (37.5) 38 (62.3)
Age (years)
≤45 5 2 (40) 3 (60) 0.646 5 2 (40) 3 (60) 0.684 5 2 (40) 3 (60) 0.967
>45 175 68 (38.9) 108 (61.1) 180 72 (40) 108 (60) 171 70 (40.9) 101 (59.1)
Previous
tumors
Without 148 58 (39.2) 90 (60.8) 0.513 151 61 (40.4) 90 (59.6) 0.488 146 59 (40.4) 87 (56.9) 0.767
With 32 12 (37.5) 20 (62.5) 34 13 (38.2) 21 (61.8) 30 13 (43.3) 17 (56.7)
Family
History
Without 152 57 (37.5) 95 (62.5) 0.407 156 60 (38.5) 96 (61.5) 0.437 149 58 (38.9) 91 (61.1) 0.418
With 16 7 (43.8) 8 (56.6) 16 7 (43.8) 9 (56.3) 14 7 (50) 7 (50)
Presentation
Asymptomatic 32 10 (31.3) 22 (68.8) 0.22 33 11 (33.3) 22 (66.7) 0.254 32 10 (31.3) 22 (68.8) 0.219
Symptomatic 148 60 (40.5) 88 (59.5) 152 63 (41.4) 89 (58.6) 144 62 (43.1) 82 (56.9)
Time to
Diagnosis
<6 months 125 52 (41.6) 73 (58.4) 0.325 128 54 (42.2) 74 (57.8) 0.424 120 53 (44.2) 67 (55.8) 0.547
>6 months 23 8 (34.8) 15 (65.2) 24 9 (37.5) 15 (62.5) 24 9 (37.5) 15 (62.5)
Localization
Colon 126 51 (40.5) 75 (59.5) 0.310 131 55 (42) 76 (58) 0.245 124 55 (44.4) 69 (55.6) 0.151
Rectum 54 19 (35.2) 35 (64.8) 54 19 (35.2) 35 (64.8) 52 17 (32.7) 35 (67.3)
However, when we did the same analysis for pathologic parameters, we found that
high accumulation of CD3+ T lymphocytes was associated with normal levels of carcinoem-
bryonic antigen (CEA) (p = 0.026), an important biomarker of different types of cancer,
including CRC [37] (Table 7). High infiltration of FoxP3+ or CD8+ T lymphocytes also
showed a tendency with normal CEA levels (p = 0.057 and p = 0.053, respectively), with
p-values very close to the statistical threshold. Additionally, the absence of lymph node
metastasis was positively correlated with a high accumulation of CD3+, CD8+, or FoxP3+ T
lymphocytes (p = 0.01, p = 0.004, and p = 0.003, respectively). We also found a tendency
associating the presence of high CD3+ infiltration with the absence of distant metastases
(p = 0.054). Finally, the high infiltration of CD3+, CD8+, and FoxP3+ T lymphocytes was
associated with TNM stages I-II (p = 0.021, p = 0.022, and p = 0.012, respectively). Together,
these results show that high infiltrations of CD3+, CD8+, or FoxP3+T lymphocytes in the
tumor margins are associated with good prognostic indicators.
Table 7. Association of tumor margin infiltration of CD3+, FoxP3+, and CD8+ T lymphocytes with pathological data.
Parameter
CD3 FoxP3 CD8
N Low (%) High (%) p N Low (%) High (%) p N Low (%) High (%) p
CEA (ng/mL)
≤10 128 44 (34.4) 84 (65.6) 0.026 132 48 (36.4) 84 (63.8) 0.057 129 48 (37.2) 81 (62.8) 0.053
>10 22 13 (59.1) 9 (40.9) 23 13 (56.5) 10 (43.5) 18 11 (61.1) 7 (38.9)
Metastasis
No 134 47 (35.1) 87 (64.9) 0.054 139 51 (36.7) 88 (63.8) 0.078 133 50 (37.6) 83 (62.4) 0.116
Yes 46 23 (50) 23 (50) 46 23 (50) 23 (50) 43 22 (51.2) 21 (48.8)




N Low (%) High (%) p N Low (%) High (%) p N Low (%) High (%) p
Tumor Size (cm)
≤4.5 103 42 (40.8) 61 (59.2) 0.185 107 46 (43.0) 61 (57) 0.116 56 44 (44) 56 (56) 0.186
>4.5 70 23 (32.9) 47 (67.1) 70 23 (32.9) 47 (67.1) 45 23 (33.8) 45 (66.2)
Histological Type
Adenocarcinoma 166 62 (37.3) 104 (62.7) 0.336 170 65 (38.2) 105 (61.8) 0.248 161 63 (39.1) 98 (60.9) 0.281
Mucinous 12 7 (58.3) 5 (41.7) 12 7 (58.3) 5 (41.7) 12 7 (58.3) 5 (41.7)
Signet ring and
mucinous 2 1 (50) 1 (50) 3 2 (66.7) 1 (33.3) 3 2 (66.7) 1 (33.3)
Differentiation
Well/Moderately 163 62 (38) 101 (62) 0.347 166 65 (39.2) 101 (60.8) 0.279 157 63 (40.1) 94 (59.9) 0.444
Poorly/undifferentiated 15 7 (46.7) 8 (53.3) 16 8 (50) 8 (50) 16 8 (50) 8 (50)
Lymph Node
Metastasis
Without 103 32 (31.1) 71 (68.9) 0.010 105 33 (31.4) 72 (68.6) 0.004 100 32 (32) 68 (68) 0.003
With 76 38 (50) 38 (50) 78 41 (52.6) 37 (47.4) 74 40 (54.1) 34 (45.9)
TNM
I-II 47 12 (25.5) 35 (74.5) 0.021 48 12 (25) 36 (75) 0.012 45 12 (26.7) 33 (73.3) 0.022
III-IV 133 58 (43.6) 76 (56.4) 136 62 (45.6) 74 (54.4) 130 60 (46.2) 70 (53.8)
Overall survival











3.4. The Presence of High CD3+, CD8+, or FoxP3+ T Lymphocyte Infiltrations Inside the Tumor or
in Its Invasive Margins Does Not Impact the Overall Survival of Patients
To determine whether lymphocyte infiltrations impacted the patients’ overall survival,
we performed log-rank tests and constructed Kaplan–Meier curves.
Our analysis did not reveal any statistically significant association between the exten-
sion of intratumor (Figure 2A–C) or tumor margin (Figure 2D–F) lymphocyte infiltrations
with the overall survival of patients. These data indicate that, in our cohort, tumor-
infiltrating lymphocytes do not impact the clinical outcome of CRC patients. Interestingly
however, while not statistically significant, our analysis revealed that high infiltrations of
CD3+, CD8+, or FoxP3+ T lymphocytes in the tumor margins resulted in increased overall
survival of 13.4 (p = 0.117), 7 (p = 0.224), and 14 months (p = 0.092), respectively. On the
other hand, high intratumor infiltrations of CD3+, CD8+, or FoxP3+ resulted in a slight
decrease in patients’ overall survival of 13.5 (p = 0.294), 9.3 (p = 0.358), and 5.3 months
(p = 0.598), respectively.
These data show that, while the intratumor infiltration by FoxP3+ lymphocytes and
infiltration of the tumor margins by CD3+, CD8+, or FoxP3+ T lymphocytes are associated
with good prognostic indicators, they do not impact the overall survival of patients.
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4. Discu sion
The interaction between tumor cells and the immune system has prompted the quan-
tification of immune i filtrates, particularly T lymp ocytes, as prognostic markers for
colorectal cancer (CRC) [35]. Herein, we analyzed the presence of lymphocyte infiltrates
(C 3+, CD8+, or FoxP3+ T lymphocytes) inside the tumor and the tumor invasive mar-
gins of CRC samples o val ate th ir prognostic potential. We were not able to find
any associations between th presence and extent of intratumor T lymphocyt infiltrates
with the clinical or pathological dat of the pati nts, indicating that, at l ast in our cohort,
intratumor lymphocytes do not influence the pathogenesis of CRC. Crucially, when we
perform the same analyses for the tumor margins, we found that the presence of high
CD3+, CD8+, or FoxP3+ T lymphocyte infiltrates were associated with TNM stages I-II,
non-invasion of lymph nodes, and normal CEA levels. These data suggest that the presence
of CD3+, CD8+, or FoxP3+ T lymphocytes in the tumor invasive margins are associated with
good prognostic indicators; however, we could not demonstrate any significant association
between any of the T lymphocyte population analyzed and the overall survival of the
patients.
In recent years, the analysis of the immune reaction inside the tumor and its invasive
margins has been suggested to predict disease-free survival and overall survival of CRC
patients, independently of the local extent of the tumor or the invasion of regional lymph
nodes (TNM stages I, II, and III) [36]. The prognostic potential of the tumor immune
reaction prompted the development of methodologies to quantify, in situ, the extent of
immune infiltrates, particularly CD3+ and CD8+ T lymphocytes [35]. Several studies show
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that high infiltrations of CD3+ and/or CD8+ T lymphocytes within CRC tumors and their
invasive margins were associated with early stages of the disease (TNM stages I-II) and
other good prognostic indicators, including absence of lymph node metastasis and distant
metastasis [19,38]. Our study corroborated these observations but only for CD3+ or CD8+ T
lymphocyte infiltrates in the tumor margins. Indeed, we were unable to find any association
between the presence of CD3+ or CD8+ T lymphocyte infiltrates inside the tumor with
markers of good CRC prognosis. In this regard, previous data has shown that, while CD8+
T lymphocytes are directly capable of killing tumor cells and positively affect prognosis
in a broad range of tumors [39–42], several other studies have shown no such correlation
with prognosis [43,44]. As such, it is possible that the tumor microenvironment could
modulate the effector function of CD8+ T lymphocytes, and that this effect may depend
on environmental variables such as the microbiome [45,46] or the tumor inflammatory
status [47]. In this regard, alteration in the intestinal microbiota has been shown to increase
intestinal tumorigenesis by enhancing inflammation and promoting T cell exhaustion [48].
Therefore, in addition to determining the presence of CD8+ T lymphocytes, future studies
should also focus on determining their effector function.
As discussed above, we also found that the high accumulation of FoxP3+ T lympho-
cytes in the tumor margins was associated with TNM stages I-II, normal CEA levels, and,
more importantly, with the non-invasion of lymph nodes. While FoxP3 can be transiently
expressed by recently activated T cells in humans, the expression of this transcription
factor also marks a population of regulatory T lymphocytes that can downregulate immune
responses and, consequently, dampen anti-tumor immune mechanisms [49–51]. Since we
did not evaluate the function of FoxP3+ lymphocytes, we were not able to discriminate
between the regulatory and non-regulatory populations of FoxP3+ lymphocytes. This is
an important limitation of our study, as it prevented us from drawing any conclusion on
the prognostic potential of the regulatory population of FoxP3-expressing lymphocytes.
However, we suggest that the immunosuppressive capacity of the regulatory population
of FoxP3-expressing lymphocytes may be important in CRC to control continuous and
aggressive inflammatory responses that may favor tumor proliferation [52,53]. Our data are
in accordance with previous data showing that high frequencies of FoxP3+ T lymphocytes
are associated with early T stages and absence of lymph node involvement [31]. However,
other studies also found associations between high FoxP3+ T lymphocyte infiltrations and
increased survival of CRC patients [32,54], which we did not find. Despite this, the high
accumulation of these cells in the tumor margins resulted in an average gain of 14 months
of the patients’ life expectancy (p = 0.092). It is important to note that previous studies have
also reported an association between high FoxP3+ lymphocyte infiltrations and advanced
CRC [33,55]. Additionally, the presence of FoxP3+ T lymphocyte infiltrates were associated
with poor prognosis in different types of cancers, including breast [26], lung [27], pan-
creatic [56], ovarian [57], and cervical [28] cancers. These data show that the presence of
FoxP3+ T lymphocytes is not always associated with a good prognosis. As this population
may downregulate immune responses, we suggest that their protective effect and their
prognostic potential may depend on the inflammatory status of the tumor. As such, future
research is required to consolidate the prognostic significance and the context wherein
FoxP3+ T lymphocytes have prognostic significance.
Our data point to the location of immune cells in relation to the tumor as an important
factor for prognosis. Indeed, while we did not find any association between intratumor
T lymphocytes with clinical or pathological data in the tumor margins, the extent of
CD3+, CD8+, and FoxP3+ lymphocyte infiltrations were all associated with good prognostic
indicators. It is tempting to speculate that the intratumor-infiltrating T lymphocytes may be
modulated by the tumor microenvironment, while in the tumor margins, these populations
are able to maintain their functions for longer periods. As discussed above, this may explain
the lack of association between the high intratumor infiltration of CD8+ T lymphocytes and
markers of good prognostic or even overall survival seen in other studies [32,35,38]. Taken
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together, the distribution of immune cells, as well as their functional capability, may be
important in predicting patients’ prognosis.
The potential limitations in analyzing tumor-infiltrating lymphocytes and perform
direct comparisons with other studies include the various criteria used in different studies
and the heterogeneity in the patterns of tumor-infiltrating lymphocytes [58]. In our study,
we accounted for this heterogeneity by staining large samples of tumor tissue with the
different lymphocyte markers, including samples with normal adjacent tissue. The assess-
ment of the immunostainings and analysis of the extent of lymphocyte infiltration in the
different areas of the tumor by an experienced pathologist ensured that the heterogeneous
expression patterns of the different markers used were seen in the context of the entire
tumor section. Moreover, automated counting methods, which are not available in all
laboratories and have been used in multiple studies, may not yield results comparable to
the usual method. In all, further studies need to take into account the heterogeneity of
lymphocyte infiltrates and evaluating methods.
In conclusion, our results indicate that only the presence of high infiltrates of CD3+,
CD8+, and FoxP3+ T lymphocytes in the tumor invasive margins are associated with good
prognostic indicators and potentially limit the aggressiveness and spread of CRC. The
presence of lymphocyte infiltrates inside the tumor was not associated with any clinical or
pathological parameter. However, while previous studies showed an association between
high lymphocytic infiltrations, particularly CD8+, and survival of CRC patients [35,38,59],
we were unable to find any association between intratumor or tumor invasive margin
lymphocyte infiltrations and overall survival. As such, while the consensus is that the
tumor immune reaction may be a good prognostic indicator for CRC, and, in some cases,
may even surpass the TNM staging system, our study suggests that this may not be the
case for all populations.
5. Conclusions
Overall, our data show that the presence of CD3+, CD8+, or FoxP3+T lymphocytes in
the tumor invasive margin are associated with the pathogenesis of CRC. However, we did
not find any association between lymphocyte infiltrations and the overall survival of CRC
patients, although high FoxP3+ T lymphocyte infiltrations in the tumor invasive margins
resulted in an increased overall survival of 14 months.
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